I-mab (IMAB)

$1.2

-0.05

(-4%)▲

Live

Insights on I-mab

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 283.9% return, outperforming this stock by 357.6%

Performance

  • $1.18
    $1.24
    $1.20
    downward going graph

    1.67%

    Downside

    Day's Volatility :4.84%

    Upside

    3.23%

    downward going graph
  • $1.17
    $7.67
    $1.20
    downward going graph

    2.5%

    Downside

    52 Weeks Volatility :84.75%

    Upside

    84.35%

    downward going graph

Returns

PeriodI-mabSector (Health Care)Index (Russel 2000)
3 Months
-60.44%
0.0%
0.0%
6 Months
-65.28%
3.0%
-0.5%
1 Year
-73.68%
7.2%
0.4%
3 Years
-98.44%
27.5%
19.1%

Highlights

Market Capitalization
160.3M
Book Value
$29.48
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.6
Wall Street Target Price
28.85
Profit Margin
0.0%
Operating Margin TTM
679.87%
Return On Assets TTM
-25.36%
Return On Equity TTM
-66.16%
Revenue TTM
-253.8M
Revenue Per Share TTM
-3.06
Quarterly Revenue Growth YOY
-62.1%
Gross Profit TTM
41.6M
EBITDA
-1.9B
Diluted Eps TTM
-3.6
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    86%Buy
    13%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for I-mab(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
14
Hold
2
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 2304.17%

Current $1.20
Target $28.85

Company Financials

FY17Y/Y Change
Revenue
11.6M
-
Net Income
-298.2M
-
Net Profit Margin
-2.6K%
-
FY18Y/Y Change
Revenue
53.8M
↑ 365.39%
Net Income
-402.8M
↑ 35.07%
Net Profit Margin
-749.02%
↑ 1831.8%
FY19Y/Y Change
Revenue
30.0M
↓ 44.22%
Net Income
-1.5B
↑ 260.43%
Net Profit Margin
-4.8K%
↓ 4090.81%
FY20Y/Y Change
Revenue
1.5B
↑ 5042.23%
Net Income
470.9M
↓ 132.43%
Net Profit Margin
30.53%
↑ 4870.36%
FY21Y/Y Change
Revenue
13.8M
↓ 94.29%
Net Income
-365.9M
↓ 595.11%
Net Profit Margin
-2.6K%
↓ 2679.23%
FY22Y/Y Change
Revenue
-32.1M
↓ 351.7%
Net Income
-349.7M
↑ 3.44%
Net Profit Margin
1.1K%
↑ 3737.25%
Q1 FY23Q/Q Change
Revenue
-1.8B
-
Net Income
-3.0B
-
Net Profit Margin
168.77%
-
FY17Y/Y Change
Total Assets
1.0B
-
Total Liabilities
1.3B
-
FY18Y/Y Change
Total Assets
2.4B
↑ 131.72%
Total Liabilities
3.3B
↑ 151.37%
FY19Y/Y Change
Total Assets
1.7B
↓ 26.87%
Total Liabilities
3.8B
↑ 13.25%
FY20Y/Y Change
Total Assets
6.3B
↑ 264.52%
Total Liabilities
706.6M
↓ 81.27%
FY21Y/Y Change
Total Assets
879.0M
↓ 11.57%
Total Liabilities
163.5M
↑ 47.41%
FY22Y/Y Change
Total Assets
590.7M
↓ 27.27%
Total Liabilities
154.5M
↑ 2.28%
Q2 FY22Q/Q Change
Total Assets
745.0M
-
Total Liabilities
145.6M
-
Q3 FY22Q/Q Change
Total Assets
5.0B
↑ 0.0%
Total Liabilities
975.5M
↑ 0.0%
Q4 FY22Q/Q Change
Total Assets
590.7M
↓ 18.39%
Total Liabilities
154.5M
↑ 9.21%
Q2 FY23Q/Q Change
Total Assets
484.2M
-
Total Liabilities
146.8M
-
FY17Y/Y Change
Operating Cash Flow
-252.2M
-
Investing Cash Flow
-157.7M
-
Financing Cash Flow
758.6M
-
FY18Y/Y Change
Operating Cash Flow
-280.7M
↑ 11.32%
Investing Cash Flow
9.5M
↓ 106.03%
Financing Cash Flow
1.5B
↑ 95.06%
FY19Y/Y Change
Operating Cash Flow
-868.0M
↑ 209.22%
Investing Cash Flow
212.5M
↑ 2136.44%
Financing Cash Flow
152.7M
↓ 89.68%
FY20Y/Y Change
Operating Cash Flow
433.6M
↓ 149.95%
Investing Cash Flow
-201.9M
↓ 195.03%
Financing Cash Flow
3.4B
↑ 2152.97%
FY21Y/Y Change
Operating Cash Flow
-152.7M
↓ 324.44%
Investing Cash Flow
-114.1M
↑ 260.18%
Financing Cash Flow
93.2M
↓ 82.74%
Q2 FY21Q/Q Change
Operating Cash Flow
-34.3M
↑ 0.0%
Investing Cash Flow
-29.5M
↑ 0.0%
Financing Cash Flow
37.7M
↑ 0.0%
Q3 FY21Q/Q Change
Operating Cash Flow
-41.1M
↑ 19.84%
Investing Cash Flow
-26.8M
↓ 9.32%
Financing Cash Flow
8.4M
↓ 77.85%
Q4 FY21Q/Q Change
Operating Cash Flow
-41.6M
↑ 0.0%
Investing Cash Flow
-27.1M
↑ 0.0%
Financing Cash Flow
8.4M
↑ 0.0%
Q1 FY22Q/Q Change
Operating Cash Flow
-45.0M
↑ 7.67%
Investing Cash Flow
39.3M
↓ 244.39%
Financing Cash Flow
2.8M
↓ 67.15%
Q2 FY22Q/Q Change
Operating Cash Flow
-42.6M
↑ 0.0%
Investing Cash Flow
37.3M
↑ 0.0%
Financing Cash Flow
2.6M
↑ 0.0%

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
I-mab
I-mab
-34.38%
-65.28%
-73.68%
-98.44%
-98.44%
Moderna, Inc.
Moderna, Inc.
-6.8%
-31.93%
-17.68%
49.48%
456.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.51%
9.46%
21.47%
49.65%
113.08%
Novo Nordisk A/s
Novo Nordisk A/s
2.45%
158.58%
283.85%
452.05%
699.12%
Seagen, Inc.
Seagen, Inc.
7.08%
3.54%
46.23%
15.75%
166.19%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
16.4%
25.65%
33.45%
95.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
I-mab
I-mab
NA
NA
NA
0.0
-0.66
-0.25
0.0
29.48
Moderna, Inc.
Moderna, Inc.
39.67
39.67
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.65
21.65
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
44.47
44.47
2.03
3.32
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.47
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.73
26.73
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
I-mab
I-mab
Buy
$160.3M
-98.44%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.4B
456.61%
39.67
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.3B
113.08%
21.65
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$423.8B
699.12%
44.47
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$38.9B
166.19%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.9B
95.64%
26.73
35.4%

Institutional Holdings

  • Hillhouse Capital Advisors, Ltd.

    8.36%

  • Vanguard Group Inc

    2.56%

  • BlackRock Inc

    2.49%

  • Artal Group S A

    1.03%

  • Bank of America Corp

    0.82%

  • JPMorgan Chase & Co

    0.72%

Corporate Announcements

  • I-mab Earnings

    I-mab’s price-to-earnings ratio stands at None

    Read More

Company Information

i-mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. it is developing felzartamab (tj202), a cd38 antibody that is in phase iii clinical trials to treat multiple myeloma and autoimmune diseases; eftansomatropin (tj101), a long-acting human growth hormone that has completed phase ii clinical trials to treat pediatric growth hormone deficiency; and olamkicept (tj301), a il-6 blocker, which is in phase ii clinical trials for the treatment of ulcerative colitis and autoimmune diseases. the company's product candidates also include enoblituzumab, a humanized b7-h3 antibody that has completed phase i clinical trials to treat head and neck cancer and other oncology diseases; efineptakin (tj107), a long-acting recombinant human il-7, which is in phase 2 clinical trials to treat glioblastoma multiforme (gbm

Organization
I-mab
Employees
0
CEO
Dr. Jingwu Zhang Zang M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs